5b: Comprehensive Study Guide for Dopamine 2 (D2) Receptor Antagonists and First-Generation Antipsychotics

Introduction to Dopamine 2 (D2) Receptor Antagonists

• Historically, medications used to treat psychosis were broadly classified as "antipsychotics." However, the field is moving away from this clinical-target nomenclature because these agents have diverse applications beyond psychosis (e.g., bipolar disorder or major depressive disorder) and not all D2 antagonists are used as antipsychotics.

• Traditional Categorization:

  • Typical Antipsychotics: Also known as neuroleptics, conventional antipsychotics, or First-Generation Antipsychotics (FGAs). Specifically, these are characterized as Dopamine Receptor Antagonists, with a primary affinity for the D2 receptor.

  • Atypical Antipsychotics: Known as Second-Generation Antipsychotics (SGAs), which will be covered elsewhere regarding their impact on both serotonin and dopamine.

• Modern Mechanism-Based Classification: Focusing on the pharmacological action (D2 antagonism) rather than the end treatment goal.

The Dopamine Hypothesis and Therapeutic Thresholds

• Dopamine Hypothesis: Psychosis and schizophrenia are historically linked to the excessive action of dopamine in the mesolimbic or mesostriatal pathways of the brain. Imaging in untreated individuals shows this heightened activity.

• D2 Antagonism: Most medications used to treat psychosis share the mechanism of blocking the D2 receptor.

• Treatment Thresholds and Efficacy:

  • To achieve an antipsychotic effect, approximately $60\% - 80\%$ of D2 receptors must be blocked.

  • Under-treatment: Blocking fewer than $60\%$ of receptors generally fails to provide therapeutic antipsychotic action.

  • Over-treatment/Toxicity: Blocking more than $80\%$ of receptors leads to a significant increase in side effect burden rather than additional therapeutic benefits.

• Historical Perspective: The term "neurolepsis" referred to an old belief that a patient had to reach a specific state of neurological suppression to effectively treat schizophrenia. Modern medicine recognizes that it is not necessary to "wipe out" all mesolimbic dopamine activity.

Understanding Potency vs. Efficacy

• Critical Distinction: Potency is not synonymous with efficacy. A more potent drug is not necessarily "better" or more effective; it simply has a higher binding affinity for a specific receptor.

• Potency: Refers to the affinity a drug has for binding to the D2 receptor.

Low-Potency D2 Antagonists

• Mechanism: At starting doses, these agents have a higher affinity for histamine and muscarinic receptors relative to D2 receptors.

• Dosing: Higher absolute doses are required to achieve the necessary $60\% - 80\%$ D2 blockade.

• Side Effect Profile:

  • Higher likelihood of sedation and anticholinergic side effects (due to histamine/muscarinic affinity).

  • Lower risk of Extrapyramidal Symptoms (EPS).

High-Potency D2 Antagonists

• Mechanism: These have a very high affinity for the D2 receptor from the outset and a much lower affinity for histamine and muscarinic receptors.

• Side Effect Profile:

  • Lower risk of sedation, weight gain, and anticholinergic side effects.

  • Significantly higher risk of EPS due to the immediate and strong binding to D2 receptors.

Clinical Implications of D2 Blockade Across Pathways

First-generation medications are "equal opportunity blockers," meaning they inhibit dopamine throughout the brain, leading to various side effects based on the pathway affected:

• Mesolimbic/Mesostriatal Pathway: Blockade reduces positive symptoms of schizophrenia (therapeutic goal).

• Mesostriatal Pathway (Off-target): Leads to EPS, including pseudo-Parkinsonism and akathisia. Long-term blockade leads to Tardive Dyskinesia (TD).

• Tuberoinfundibular Pathway: Blockade leads to prolactin elevation and associated side effects (e.g., galactorrhea, sexual dysfunction).

• Mesocortical Pathway: Schizophrenia often involves too little dopamine in this pathway; blocking it further can create or exacerbate "secondary negative symptoms."

• Reward/Pleasure Pathways: Blocking dopamine here can result in a loss of the sense of reward, compounding negative symptoms.

Medical Emergencies: NMS vs. Serotonin Syndrome

Providers must distinguish between Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome (SS), as they present similarly but have different causes and treatments.

Neuroleptic Malignant Syndrome (NMS)

• Causative Agent: Any dopamine-blocking medication (FGAs, SGAs, and others). It is a class effect, though relatively rare.

• Onset: Typically develops within the first 7 days of starting or increasing a dose ($2/3$ of cases occur in this window). It is rarely seen past the first month of treatment.

• Neuromuscular Findings: "Lead pipe" muscle rigidity and slower reflexes (Parkinsonian-like).

• Other Symptoms: Elevated heart rate, blood pressure, and temperature (hyperthermia).

• Nature: An idiosyncratic reaction, not an overdose or toxicity.

Serotonin Syndrome (SS)

• Causative Agent: Medications that increase serotonin levels.

• Onset: Rapid onset, usually within 24 hours.

• Neuromuscular Findings: Hyperactive state, clonus (involuntary muscle contractions), increased reflexes, and tremors.

• Other Symptoms: Shared Autonomic instability (HR, BP, Temp elevations) with NMS.

Management of NMS

1. Immediate Action: Stop the offending agent and transfer to a hospital (medical emergency). This is NOT an outpatient condition.

2. Supportive Care: Reducing temperature, correcting dehydration, correcting electrolyte imbalances, and potentially mechanical ventilation.

3. Pharmacological Interventions:

   • IV Benzodiazepines (e.g., Ativan/Lorazepam, Valium/Diazepam).

   • IV Dantrolene (Skeletal muscle relaxant used for extreme hyperthermia).

   • Dopamine Agonists: Bromocriptine or Amantadine.

4. Refractory Cases: Electroconvulsive Therapy (ECT).

Resuming Treatment After NMS

• There is no absolute contraindication to resuming antipsychotics once NMS resolves, though recurrence happens in estimated $10\% - 30\%$ of cases.

• Guidelines:

  • Wait for complete resolution.

  • Start at the lowest possible dose.

  • Preference: Second-generation (SGA) over First-generation (FGA).

  • If FGA must be used, choose low-potency over high-potency.

  • Avoid things that exacerbate NMS (e.g., dehydration, potentially lithium).

Prototype: Chlorpromazine (Low-Potency FGA)

• History: The first conventional antipsychotic discovered; the prototypical "dirty drug."

• Receptor Profile: High affinity for many receptors, including histamine and muscarinic, requiring higher doses to reach D2 blockade goals.

• Specific Risks:

  • Seizure Threshold: The only FGA associated with significantly lowering the seizure threshold (most others with this risk are SGAs).

  • Photosensitivity: Part of the phenothiazine class. Use the mnemonic "Pheno-Photo."

  • Pigment Changes: Prolonged high-dose use can cause a benign, blue-grayish skin discoloration in sun-exposed areas and corneal deposits (reversible).

Prototype: Haloperidol (Haldol) (High-Potency FGA)

• Receptor Profile: Highly specific to D2 receptors with almost no anticholinergic or antihistamine activity. It is not a "dirty drug."

• Clinical Use: Frequently used for delirium due to the lack of anticholinergic side effects.

• Administration: Oral, Intramuscular (IM) acute dose, or long-acting Depot.

• IV Administration Warning: While possible, IV use is avoided due to a high risk of prolonging the QTc interval.

• Side Effects:

  • Minimal weight gain and low sedation.

  • High incidence of EPS and long-term risk of Tardive Dyskinesia.

  • Possible orthostatic hypotension (alpha receptor involvement).

Other Potential Side Effects of FGAs

• Agranulocytosis: A dangerous reduction in white blood cell count.

• Ocular Issues: Deposits in the lenses or cornea, which may eventually lead to cataracts.

• Nonspecific: General sedation and anticholinergic effects (dry mouth, urinary retention, etc.).

• Antipsychotic Overdose: Management is purely supportive; there is no specific antidote or laboratory monitoring required beyond standard overdose protocols.